Cargando…

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

Forde et al.(1) reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).

Detalles Bibliográficos
Autores principales:	Leal, Ticiana A., Ramalingam, Suresh S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Spotlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381414/ https://www.ncbi.nlm.nih.gov/pubmed/35858590 http://dx.doi.org/10.1016/j.xcrm.2022.100691

Ejemplares similares

Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting
por: Chien, A. Jo, et al.
Publicado: (2022)

FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
por: Pai‐Scherf, Lee, et al.
Publicado: (2017)

Learning while treating: Gain-of-function STAT6 variants in severe allergic disease
por: Smith, Tukisa D., et al.
Publicado: (2023)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
por: Powell, Kerrington, et al.
Publicado: (2021)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
por: Kepp, Oliver, et al.
Publicado: (2020)

Long noncoding RNA amplified in lung cancer rewires cancer pathways
por: Martínez-Terroba, Elena, et al.
Publicado: (2020)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Transition metal ion-doped ferrites nanoparticles for bioimaging and cancer therapy
por: Du, Hui, et al.
Publicado: (2021)

Weekly osimertinib dosing prevents EGFR mutant tumor cells destined to home mouse lungs
por: Butle, Ashwin, et al.
Publicado: (2021)

FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Organoids as a tool in drug discovery and patient-specific therapy for head and neck cancer
por: Done, Aaron J., et al.
Publicado: (2023)

Non-canonical ubiquitylation makes its mark on Rap2 and cell motility
por: Caswell, Patrick T.
Publicado: (2022)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Lung function testing in the COVID-19 endemic
por: Hull, James H, et al.
Publicado: (2020)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

The ongoing mystery of renal cell cancer
por: Yang, James C.
Publicado: (2021)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis
por: Benedetto Tiz, Davide, et al.
Publicado: (2022)

Genetic insights into lung function inform better management of respiratory diseases
por: Qin, Na, et al.
Publicado: (2023)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

An improved DNA method to unambiguously detect small hive beetle Aethina tumida, an invasive pest of honeybee colonies
por: Silacci, Paolo, et al.
Publicado: (2018)

Worksite-based intensive lifestyle therapies for diabetes remission
por: Varady, Krista A., et al.
Publicado: (2022)

Clinical Trials to Gain FDA Approval for Computerized Cognitive Training: What Is the Ideal Control Condition?
por: Motter, Jeffrey N., et al.
Publicado: (2016)

Advances in co-opting anti-depressant drugs in glioma therapy
por: Pant, Ayush, et al.
Publicado: (2022)

CD8(+) T cells: An ineffective armor against prolonged COVID-19 in cancer patients
por: Van Oekelen, Oliver, et al.
Publicado: (2022)

Lessons from early life: understanding development to expand stem cells and treat cancers
por: Bain, Fiona M., et al.
Publicado: (2022)

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations
por: Odogwu, Lauretta, et al.
Publicado: (2018)

Co-targeting TGF-β and PD-L1 with radiation therapy: The Goldilocks principle
por: Bakhoum, Samuel F., et al.
Publicado: (2021)

Magnetic resonance imaging in a patient with cardiac resynchronization therapy‐defibrillator and two abandoned leads
por: Lüsebrink, Enzo, et al.
Publicado: (2022)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Prescribing of FDA-approved and compounded hormone therapy differs by specialty
por: Constantine, Ginger D., et al.
Publicado: (2016)

Current FDA-Approved Therapies for High-Grade Malignant Gliomas
por: Fisher, Jacob P., et al.
Publicado: (2021)

Potential feasibility of a novel over‐the‐wire microelectrode catheter for recording coronary sinus electrograms in patients with cardiac resynchronization therapy devices
por: Okada, Masato, et al.
Publicado: (2023)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

The double face of cold in cancer
por: Voskarides, Konstantinos
Publicado: (2022)

Ventricular fibrillation count by noise oversensing in a cardiac resynchronization therapy‐defibrillator induced by side branch protection during percutaneous coronary intervention
por: Tanabe, Sho, et al.
Publicado: (2022)

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_mhul5l42i2kpgu195tvl2mcjqm